O	0	3	DNA	DNA	NN	B-NP
O	4	10	damage	damage	NN	I-NP
O	11	18	induces	induce	VBZ	B-VP
O	19	20	a	a	DT	B-NP
O	21	26	novel	novel	JJ	I-NP
O	27	30	p53	p53	NN	I-NP
O	30	31	-	-	HYPH	B-NP
O	31	39	survivin	survivin	NN	I-NP
O	40	49	signaling	signaling	NN	I-NP
O	50	57	pathway	pathway	NN	I-NP
O	58	68	regulating	regulate	VBG	B-VP
B-Cell	69	73	cell	cell	NN	B-NP
O	74	79	cycle	cycle	NN	I-NP
O	80	83	and	and	CC	O
O	84	93	apoptosis	apoptosis	NN	B-NP
O	94	96	in	in	IN	B-PP
B-Cell	97	102	acute	acute	JJ	B-NP
I-Cell	103	116	lymphoblastic	lymphoblastic	JJ	I-NP
I-Cell	117	125	leukemia	leukemia	NN	I-NP
I-Cell	126	131	cells	cell	NNS	I-NP
O	131	132	.	.	.	O

O	134	142	Survivin	Survivin	NN	B-NP
O	143	145	is	be	VBZ	B-VP
O	146	147	a	a	DT	B-NP
O	148	153	novel	novel	JJ	I-NP
O	154	160	member	member	NN	I-NP
O	161	163	of	of	IN	B-PP
O	164	167	the	the	DT	B-NP
O	168	177	inhibitor	inhibitor	NN	I-NP
O	178	180	of	of	IN	B-PP
O	181	190	apoptosis	apoptosis	NN	B-NP
O	191	198	protein	protein	NN	I-NP
O	199	200	(	(	(	O
O	200	203	IAP	IAP	NN	B-NP
O	203	204	)	)	)	O
O	205	211	family	family	NN	B-NP
O	211	212	.	.	.	O

O	213	217	Here	Here	RB	B-ADVP
O	218	220	we	we	PRP	B-NP
O	221	227	report	report	VBP	B-VP
O	228	232	that	that	IN	B-SBAR
O	233	236	the	the	DT	B-NP
O	237	253	chemotherapeutic	chemotherapeutic	JJ	I-NP
O	254	258	drug	drug	NN	I-NP
O	259	270	doxorubicin	doxorubicin	NN	I-NP
O	270	271	,	,	,	O
O	272	273	a	a	DT	B-NP
O	274	277	DNA	DNA	NN	I-NP
O	277	278	-	-	HYPH	O
O	278	286	damaging	damage	VBG	B-VP
O	287	292	agent	agent	NN	B-NP
O	292	293	,	,	,	O
O	294	303	activates	activate	VBZ	B-VP
O	304	305	a	a	DT	B-NP
O	306	309	p53	p53	NN	I-NP
O	309	310	-	-	HYPH	B-NP
O	310	318	survivin	survivin	NN	I-NP
O	319	328	signaling	signaling	NN	I-NP
O	329	336	pathway	pathway	NN	I-NP
O	337	345	inducing	induce	VBG	B-VP
B-Cell	346	350	cell	cell	NN	B-NP
O	351	356	cycle	cycle	NN	I-NP
O	357	363	arrest	arrest	NN	I-NP
O	364	367	and	and	CC	I-NP
O	368	377	apoptosis	apoptosis	NN	I-NP
O	378	380	in	in	IN	B-PP
O	381	390	childhood	childhood	NN	B-NP
B-Cancer	391	396	acute	acute	JJ	I-NP
I-Cancer	397	410	lymphoblastic	lymphoblastic	JJ	I-NP
I-Cancer	411	419	leukemia	leukemia	NN	I-NP
O	420	421	(	(	(	O
B-Cancer	421	424	ALL	ALL	NN	B-NP
O	424	425	)	)	)	O
O	425	426	.	.	.	O

O	427	436	Treatment	Treatment	NN	B-NP
O	437	439	of	of	IN	B-PP
B-Cell	440	444	wild	wild	JJ	B-NP
I-Cell	444	445	-	-	HYPH	I-NP
I-Cell	445	449	type	type	NN	I-NP
I-Cell	450	451	(	(	(	I-NP
I-Cell	451	453	wt	wt	NN	I-NP
I-Cell	453	454	)	)	)	I-NP
I-Cell	455	458	p53	p53	NN	I-NP
I-Cell	459	462	ALL	ALL	NN	I-NP
I-Cell	463	468	cells	cell	NNS	I-NP
O	469	470	(	(	(	O
B-Cell	470	472	EU	EU	NN	B-NP
I-Cell	472	473	-	-	HYPH	B-NP
I-Cell	473	474	3	3	CD	I-NP
I-Cell	475	479	cell	cell	NN	I-NP
I-Cell	480	484	line	line	NN	I-NP
O	484	485	)	)	)	O
O	486	490	with	with	IN	B-PP
O	491	502	doxorubicin	doxorubicin	NN	B-NP
O	503	509	caused	cause	VBD	B-VP
O	510	522	accumulation	accumulation	NN	B-NP
O	523	525	of	of	IN	B-PP
O	526	529	p53	p53	NN	B-NP
O	529	530	,	,	,	O
O	531	540	resulting	result	VBG	B-VP
O	541	543	in	in	IN	B-PP
O	544	552	dramatic	dramatic	JJ	B-ADJP
O	553	557	down	down	RB	B-ADVP
O	557	558	-	-	HYPH	O
O	558	568	regulation	regulation	NN	B-NP
O	569	571	of	of	IN	B-PP
O	572	580	survivin	survivin	NN	B-NP
O	580	581	,	,	,	O
O	582	591	depletion	depletion	NN	B-NP
O	592	594	of	of	IN	B-PP
B-Cell	595	600	cells	cell	NNS	B-NP
O	601	603	in	in	IN	B-PP
O	604	605	G	G	NN	B-NP
O	605	606	(	(	(	O
O	606	607	2	2	CD	B-NP
O	607	608	)	)	)	O
O	608	609	/	/	SYM	B-NP
O	609	610	M	M	NN	I-NP
O	610	611	,	,	,	O
O	612	615	and	and	CC	O
O	616	625	apoptosis	apoptosis	NN	B-NP
O	626	627	(	(	(	O
O	627	636	increased	increase	VBN	B-VP
O	637	640	sub	sub	AFX	O
O	640	641	-	-	HYPH	O
O	641	642	G	G	NN	B-NP
O	642	643	(	(	(	O
O	643	644	1	1	CD	B-NP
O	644	645	)	)	)	O
O	646	657	compartment	compartment	NN	B-NP
O	657	658	)	)	)	O
O	658	659	.	.	.	O

O	660	662	In	In	IN	B-PP
O	663	671	contrast	contrast	NN	B-NP
O	671	672	,	,	,	O
O	673	684	doxorubicin	doxorubicin	NN	B-NP
O	685	694	treatment	treatment	NN	I-NP
O	695	697	of	of	IN	B-PP
B-Cell	698	704	mutant	mutant	NN	B-NP
I-Cell	705	706	(	(	(	O
I-Cell	706	709	mut	mut	NN	B-NP
I-Cell	709	710	)	)	)	O
I-Cell	711	714	p53	p53	NN	B-NP
I-Cell	715	720	cells	cell	NNS	I-NP
O	721	722	(	(	(	O
B-Cell	722	724	EU	EU	NN	B-NP
I-Cell	724	725	-	-	HYPH	O
I-Cell	725	726	6	6	CD	B-NP
I-Cell	726	727	/	/	SYM	I-NP
I-Cell	727	730	ALL	ALL	NN	I-NP
I-Cell	731	735	line	line	NN	I-NP
O	735	736	)	)	)	O
O	737	739	up	up	RB	B-ADVP
O	739	740	-	-	HYPH	B-VP
O	740	749	regulated	regulate	VBN	B-NP
O	750	758	survivin	survivin	NN	I-NP
O	759	762	and	and	CC	O
O	763	770	induced	induce	VBD	B-VP
O	771	772	G	G	NN	B-NP
O	772	773	(	(	(	O
O	773	774	2	2	CD	B-NP
O	774	775	)	)	)	O
O	775	776	/	/	SYM	B-NP
O	776	777	M	M	NN	I-NP
O	778	784	arrest	arrest	NN	I-NP
O	785	792	without	without	IN	B-PP
O	793	801	inducing	induce	VBG	B-VP
O	802	811	apoptosis	apoptosis	NN	B-NP
O	811	812	.	.	.	O

O	813	820	However	However	RB	B-ADVP
O	820	821	,	,	,	O
O	822	830	treating	treat	VBG	B-VP
B-Cell	831	833	EU	EU	NN	B-NP
I-Cell	833	834	-	-	HYPH	O
I-Cell	834	835	6	6	CD	B-NP
O	836	840	with	with	IN	B-PP
O	841	845	anti	anti	AFX	B-NP
O	845	846	-	-	HYPH	I-NP
O	846	854	survivin	survivin	NN	I-NP
O	855	864	antisense	antisense	NN	I-NP
O	865	877	resensitized	resensitize	VBD	B-VP
O	878	883	these	these	DT	B-NP
B-Cell	884	889	cells	cell	NNS	I-NP
O	890	892	to	to	TO	B-PP
O	893	904	doxorubicin	doxorubicin	NN	B-NP
O	904	905	,	,	,	O
O	906	915	resulting	result	VBG	B-VP
O	916	918	in	in	IN	B-PP
O	919	928	apoptosis	apoptosis	NN	B-NP
O	928	929	.	.	.	O

O	930	934	With	With	IN	B-PP
O	935	936	a	a	DT	B-NP
B-Cell	937	940	p53	p53	NN	I-NP
I-Cell	940	941	-	-	HYPH	B-NP
I-Cell	941	945	null	null	JJ	I-NP
I-Cell	946	950	cell	cell	NN	I-NP
I-Cell	951	955	line	line	NN	I-NP
O	956	957	(	(	(	O
B-Cell	957	959	EU	EU	NN	B-NP
I-Cell	959	960	-	-	HYPH	B-NP
I-Cell	960	961	4	4	CD	I-NP
I-Cell	961	962	)	)	)	O
O	962	963	,	,	,	O
O	964	972	although	although	IN	B-SBAR
O	973	984	doxorubicin	doxorubicin	NN	B-NP
O	985	994	treatment	treatment	NN	I-NP
O	995	1003	arrested	arrest	VBD	B-VP
B-Cell	1004	1009	cells	cell	NNS	B-NP
O	1010	1012	in	in	IN	B-PP
O	1013	1014	G	G	NN	B-NP
O	1014	1015	(	(	(	O
O	1015	1016	2	2	CD	B-NP
O	1016	1017	)	)	)	O
O	1017	1018	/	/	SYM	O
O	1018	1019	M	M	NN	B-NP
O	1019	1020	,	,	,	O
O	1021	1029	survivin	survivin	NN	B-NP
O	1030	1040	expression	expression	NN	I-NP
O	1041	1044	was	be	VBD	B-VP
O	1045	1054	unchanged	unchanged	JJ	B-ADJP
O	1054	1055	,	,	,	O
O	1056	1059	and	and	CC	O
B-Cell	1060	1065	cells	cell	NNS	B-NP
O	1066	1075	underwent	undergo	VBD	B-VP
O	1076	1080	only	only	RB	B-NP
O	1081	1088	limited	limited	JJ	I-NP
O	1089	1098	apoptosis	apoptosis	NN	I-NP
O	1098	1099	.	.	.	O

O	1100	1107	However	However	RB	B-ADVP
O	1107	1108	,	,	,	O
O	1109	1111	re	re	AFX	B-NP
O	1111	1112	-	-	HYPH	I-NP
O	1112	1122	expression	expression	NN	B-NP
O	1123	1125	of	of	IN	B-PP
O	1126	1128	wt	wt	NN	B-NP
O	1128	1129	-	-	HYPH	B-NP
O	1129	1132	p53	p53	NN	I-NP
O	1133	1135	in	in	IN	B-PP
B-Cell	1136	1138	EU	EU	NN	B-NP
I-Cell	1138	1139	-	-	HYPH	O
I-Cell	1139	1140	4	4	CD	B-NP
I-Cell	1141	1146	cells	cell	NNS	I-NP
O	1147	1152	could	could	MD	B-VP
O	1153	1160	restore	restore	VB	I-VP
O	1161	1164	the	the	DT	B-NP
O	1165	1176	doxorubicin	doxorubicin	NN	I-NP
O	1176	1177	-	-	HYPH	B-NP
O	1177	1180	p53	p53	NN	I-NP
O	1180	1181	-	-	HYPH	I-NP
O	1181	1189	survivin	survivin	NN	I-NP
O	1190	1197	pathway	pathway	NN	I-NP
O	1197	1198	,	,	,	O
O	1199	1208	resulting	result	VBG	B-VP
O	1209	1211	in	in	IN	B-PP
O	1212	1225	significantly	significantly	RB	B-NP
O	1226	1235	decreased	decrease	VBN	I-NP
O	1236	1244	survivin	survivin	NN	I-NP
O	1245	1255	expression	expression	NN	I-NP
O	1256	1259	and	and	CC	O
O	1260	1269	increased	increase	VBN	B-NP
O	1270	1279	apoptosis	apoptosis	NN	I-NP
O	1280	1282	in	in	IN	B-PP
O	1283	1288	these	these	DT	B-NP
B-Cell	1289	1294	cells	cell	NNS	I-NP
O	1295	1300	after	after	IN	B-PP
O	1301	1312	doxorubicin	doxorubicin	NN	B-NP
O	1313	1322	treatment	treatment	NN	I-NP
O	1322	1323	.	.	.	O

O	1324	1333	Following	Follow	VBG	B-PP
O	1334	1348	cotransfection	cotransfection	NN	B-NP
O	1349	1351	of	of	IN	B-PP
B-Cell	1352	1355	p53	p53	NN	B-NP
I-Cell	1355	1356	-	-	HYPH	B-NP
I-Cell	1356	1360	null	null	JJ	I-NP
I-Cell	1361	1363	EU	EU	NN	I-NP
I-Cell	1363	1364	-	-	HYPH	O
I-Cell	1364	1365	4	4	CD	B-NP
I-Cell	1366	1371	cells	cell	NNS	I-NP
O	1372	1376	with	with	IN	B-PP
O	1377	1385	survivin	survivin	NN	B-NP
O	1386	1394	promoter	promoter	NN	I-NP
O	1394	1395	-	-	HYPH	B-NP
O	1395	1405	luciferase	luciferase	NN	I-NP
O	1406	1416	constructs	construct	NNS	I-NP
O	1417	1420	and	and	CC	O
O	1421	1427	either	either	CC	O
O	1428	1430	wt	wt	NN	B-NP
O	1430	1431	-	-	HYPH	O
O	1431	1434	p53	p53	NN	B-NP
O	1435	1437	or	or	CC	O
O	1438	1447	different	different	JJ	B-NP
O	1448	1451	mut	mut	NN	I-NP
O	1451	1452	-	-	HYPH	B-NP
O	1452	1455	p53	p53	NN	I-NP
O	1456	1466	expression	expression	NN	I-NP
O	1467	1474	vectors	vector	NNS	I-NP
O	1474	1475	,	,	,	O
O	1476	1478	wt	wt	NN	B-NP
O	1478	1479	-	-	HYPH	I-NP
O	1479	1482	p53	p53	NN	I-NP
O	1483	1492	inhibited	inhibit	VBD	B-VP
O	1493	1501	survivin	survivin	NN	B-NP
O	1502	1510	promoter	promoter	NN	I-NP
O	1511	1519	activity	activity	NN	I-NP
O	1519	1520	;	;	:	O
O	1521	1524	p53	p53	NN	B-NP
O	1524	1525	-	-	HYPH	O
O	1525	1533	mediated	mediate	VBN	B-NP
O	1534	1544	inhibition	inhibition	NN	I-NP
O	1545	1550	could	could	MD	B-VP
O	1551	1553	be	be	VB	I-VP
O	1554	1563	abrogated	abrogate	VBN	I-VP
O	1564	1566	by	by	IN	B-PP
O	1567	1581	overexpression	overexpression	NN	B-NP
O	1582	1584	of	of	IN	B-PP
O	1585	1591	murine	murine	JJ	B-NP
O	1592	1598	double	double	JJ	I-NP
O	1599	1606	minute2	minute2	NN	I-NP
O	1607	1608	(	(	(	O
O	1608	1612	MDM2	MDM2	NN	B-NP
O	1612	1613	)	)	)	O
O	1614	1621	protein	protein	NN	B-NP
O	1621	1622	.	.	.	O

O	1623	1631	Together	Together	RB	B-ADVP
O	1631	1632	,	,	,	O
O	1633	1638	these	these	DT	B-NP
O	1639	1646	studies	study	NNS	I-NP
O	1647	1653	define	define	VBP	B-VP
O	1654	1655	a	a	DT	B-NP
O	1656	1661	novel	novel	JJ	I-NP
O	1662	1665	p53	p53	NN	I-NP
O	1665	1666	-	-	HYPH	B-NP
O	1666	1674	survivin	survivin	NN	I-NP
O	1675	1684	signaling	signaling	NN	I-NP
O	1685	1692	pathway	pathway	NN	I-NP
O	1693	1702	activated	activate	VBN	B-VP
O	1703	1705	by	by	IN	B-PP
O	1706	1709	DNA	DNA	NN	B-NP
O	1710	1716	damage	damage	NN	I-NP
O	1717	1721	that	that	WDT	B-NP
O	1722	1729	results	result	VBZ	B-VP
O	1730	1732	in	in	IN	B-PP
O	1733	1737	down	down	RB	B-NP
O	1737	1738	-	-	HYPH	I-NP
O	1738	1748	regulation	regulation	NN	B-NP
O	1749	1751	of	of	IN	B-PP
O	1752	1760	survivin	survivin	NN	B-NP
O	1760	1761	,	,	,	O
B-Cell	1762	1766	cell	cell	NN	B-NP
O	1767	1772	cycle	cycle	NN	I-NP
O	1773	1779	arrest	arrest	NN	I-NP
O	1779	1780	,	,	,	O
O	1781	1784	and	and	CC	O
O	1785	1794	apoptosis	apoptosis	NN	B-NP
O	1794	1795	.	.	.	O

O	1796	1807	Furthermore	Furthermore	RB	B-ADVP
O	1807	1808	,	,	,	O
O	1809	1812	our	our	PRP$	B-NP
O	1813	1817	data	datum	NNS	I-NP
O	1818	1826	indicate	indicate	VBP	B-VP
O	1827	1831	that	that	IN	B-SBAR
O	1832	1836	loss	loss	NN	B-NP
O	1837	1839	of	of	IN	B-PP
O	1840	1842	wt	wt	NN	B-NP
O	1842	1843	-	-	HYPH	B-NP
O	1843	1846	p53	p53	NN	I-NP
O	1847	1855	function	function	NN	I-NP
O	1856	1858	in	in	IN	B-PP
B-Cell	1859	1864	tumor	tumor	NN	B-NP
I-Cell	1865	1870	cells	cell	NNS	I-NP
O	1871	1874	may	may	MD	B-VP
O	1875	1885	contribute	contribute	VB	I-VP
O	1886	1888	to	to	TO	B-PP
O	1889	1891	up	up	RB	B-ADVP
O	1891	1892	-	-	HYPH	O
O	1892	1902	regulation	regulation	NN	B-NP
O	1903	1905	of	of	IN	B-PP
O	1906	1914	survivin	survivin	NN	B-NP
O	1915	1918	and	and	CC	I-NP
O	1919	1929	resistance	resistance	NN	I-NP
O	1930	1932	to	to	TO	B-PP
O	1933	1936	DNA	DNA	NN	B-NP
O	1936	1937	-	-	HYPH	O
O	1937	1945	damaging	damage	VBG	B-NP
O	1946	1952	agents	agent	NNS	I-NP
O	1952	1953	.	.	.	O

